AU2012382406B2 - Nucleic acids for treatment of allergies - Google Patents

Nucleic acids for treatment of allergies Download PDF

Info

Publication number
AU2012382406B2
AU2012382406B2 AU2012382406A AU2012382406A AU2012382406B2 AU 2012382406 B2 AU2012382406 B2 AU 2012382406B2 AU 2012382406 A AU2012382406 A AU 2012382406A AU 2012382406 A AU2012382406 A AU 2012382406A AU 2012382406 B2 AU2012382406 B2 AU 2012382406B2
Authority
AU
Australia
Prior art keywords
nucleic acid
acid molecule
allergen
sequence
lamp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012382406A
Other languages
English (en)
Other versions
AU2012382406A1 (en
AU2012382406A2 (en
Inventor
William Hearl
Teri Heiland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomic Therapeutics Inc
Original Assignee
Immunomic Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomic Therapeutics Inc filed Critical Immunomic Therapeutics Inc
Publication of AU2012382406A1 publication Critical patent/AU2012382406A1/en
Publication of AU2012382406A2 publication Critical patent/AU2012382406A2/en
Application granted granted Critical
Publication of AU2012382406B2 publication Critical patent/AU2012382406B2/en
Priority to AU2018200625A priority Critical patent/AU2018200625B2/en
Priority to AU2019250227A priority patent/AU2019250227B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AU2012382406A 2012-06-15 2012-06-15 Nucleic acids for treatment of allergies Active AU2012382406B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2018200625A AU2018200625B2 (en) 2012-06-15 2018-01-25 Nucleic acids for treatment of allergies
AU2019250227A AU2019250227B2 (en) 2012-06-15 2019-10-18 Nucleic acids for treatment of allergies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/042552 WO2013187906A1 (en) 2012-06-15 2012-06-15 Nucleic acids for treatment of allergies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018200625A Division AU2018200625B2 (en) 2012-06-15 2018-01-25 Nucleic acids for treatment of allergies

Publications (3)

Publication Number Publication Date
AU2012382406A1 AU2012382406A1 (en) 2014-12-18
AU2012382406A2 AU2012382406A2 (en) 2015-04-16
AU2012382406B2 true AU2012382406B2 (en) 2017-12-07

Family

ID=49758576

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2012382406A Active AU2012382406B2 (en) 2012-06-15 2012-06-15 Nucleic acids for treatment of allergies
AU2018200625A Active AU2018200625B2 (en) 2012-06-15 2018-01-25 Nucleic acids for treatment of allergies
AU2019250227A Active AU2019250227B2 (en) 2012-06-15 2019-10-18 Nucleic acids for treatment of allergies

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2018200625A Active AU2018200625B2 (en) 2012-06-15 2018-01-25 Nucleic acids for treatment of allergies
AU2019250227A Active AU2019250227B2 (en) 2012-06-15 2019-10-18 Nucleic acids for treatment of allergies

Country Status (20)

Country Link
US (3) US9744230B2 (OSRAM)
EP (2) EP2861240B1 (OSRAM)
JP (1) JP5807994B2 (OSRAM)
KR (2) KR102107646B1 (OSRAM)
CN (2) CN107937423A (OSRAM)
AU (3) AU2012382406B2 (OSRAM)
BR (1) BR112014031327B1 (OSRAM)
CA (1) CA2876824C (OSRAM)
CY (1) CY1123769T1 (OSRAM)
DK (1) DK2861240T3 (OSRAM)
ES (1) ES2831723T3 (OSRAM)
HR (1) HRP20201815T1 (OSRAM)
HU (1) HUE052481T2 (OSRAM)
IL (4) IL236174B (OSRAM)
LT (1) LT2861240T (OSRAM)
PL (1) PL2861240T3 (OSRAM)
PT (1) PT2861240T (OSRAM)
RS (1) RS61098B1 (OSRAM)
SI (1) SI2861240T1 (OSRAM)
WO (1) WO2013187906A1 (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160185831A1 (en) * 2011-06-14 2016-06-30 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
RS61098B1 (sr) 2012-06-15 2020-12-31 Immunomic Therapeutics Inc Nukleinske kiseline za lečenje alergija
CN105120894B (zh) 2012-10-30 2019-02-15 阿拉沃克斯有限公司 新颖的免疫治疗分子和其用途
JP7007534B2 (ja) 2013-09-25 2022-01-24 アラヴァックス ピーティーワイ リミテッド 新規免疫療法組成物およびその使用
BR112016030439A2 (pt) * 2014-06-23 2018-07-17 Immunomic Therapeutics Inc ácidos nucléicos para o tratamento de alergias ao amendoim.
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10143742B2 (en) 2015-02-20 2018-12-04 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
KR20180093954A (ko) 2015-12-23 2018-08-22 메디진 이뮤노테라피스 게엠바하 항원-특이적 tcr의 신규 생성
EP3541420A2 (en) 2016-11-16 2019-09-25 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
JP7610349B2 (ja) * 2017-04-22 2025-01-08 イミュノミック セラピューティックス， インコーポレイテッド 改良ｌａｍｐ構築物
KR20200016224A (ko) * 2017-05-02 2020-02-14 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 lamp (리소솜 연관 막 단백질) 구축물
SG11202000419QA (en) 2017-07-18 2020-02-27 Before Brands Inc Methods for making mixed allergen compositions
CA3096363C (en) * 2018-04-06 2024-04-16 Slsbio Co., Ltd. Novel epitope of immunoglobulin e, antibody binding thereto, and kit for analyzing immunoglobulin e in sample containing same
WO2019216396A1 (ja) 2018-05-11 2019-11-14 アステラス製薬株式会社 甲殻類アレルギー治療のための核酸
WO2019216394A1 (ja) 2018-05-11 2019-11-14 アステラス製薬株式会社 ダニアレルギー治療のための核酸
WO2019222281A1 (en) * 2018-05-15 2019-11-21 Immunomic Therapeutics, Inc Improved lamp constructs comprising allergens
SG11202108043PA (en) 2019-01-23 2021-08-30 Before Brands Inc Methods for making mixed allergen compositions
KR102811748B1 (ko) * 2019-03-13 2025-05-26 주식회사 마크로젠 알레르기 치료를 위한 에피토프-기반 접근법 및 크론병에 대한 억제제
JP2024517463A (ja) * 2021-05-04 2024-04-22 ソヴィダ ソリューションズ リミテッド ニコチンアミドアデニンジヌクレオチド（ｎａｄ）組成物、それらの製造方法、及びそれらの使用方法
WO2023013785A1 (ja) * 2021-08-06 2023-02-09 花王株式会社 Ｓｎａｒｅを活用した核酸構築物
FI20237105A9 (en) 2023-05-29 2024-11-30 Onni Biotechnologies Oy Modified natural killer cells with enhanced cytotoxic action and greater survival

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001076642A1 (en) * 2000-04-07 2001-10-18 The Regents Of The University Of California Synergistic improvements to polynucleotide vaccines
WO2002080851A2 (en) * 2001-04-05 2002-10-17 The Johns Hopkins University Chimeric vaccines

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD335810S (en) 1990-07-02 1993-05-25 Dick-Ming Asien Handle for luggage or similar article
US6982326B1 (en) 1991-07-12 2006-01-03 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from Japanese cedar pollen
US6090386A (en) 1991-07-12 2000-07-18 Griffith; Irwin J. T cell peptides of the CRX JII allergen
WO1994024281A1 (en) * 1993-04-14 1994-10-27 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
NZ258701A (en) 1992-11-12 1996-11-26 Immulogic Pharma Corp Allergenic cry j ii proteins and coding sequences from japanese cedar pollen, their production and therapeutic use
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
JP3649460B2 (ja) 1993-11-05 2005-05-18 明治乳業株式会社 スギ花粉アレルゲンＣｒｙ ｊ ＩＩエピトープ
GB9516760D0 (en) 1995-08-16 1995-10-18 Sandoz Ltd Organic compounds
WO1997024139A1 (en) 1995-12-29 1997-07-10 University Of Arkansas Peanut allergens and methods
CN102286077A (zh) 1996-06-14 2011-12-21 明治乳业株式会社 T细胞表位肽
WO2002074250A2 (en) 2001-03-16 2002-09-26 Panacea Pharmaceuticals Methods and reagents for decreasing clinical reaction to allergy
US20060003148A1 (en) 2004-06-30 2006-01-05 Zwynenburg James L Interlocking polymeric foam floor underlayment and process for making
US20060216315A1 (en) * 2005-03-16 2006-09-28 Yoo Tai J Cockroach allergen gene expression and delivery systems and uses
US20090304738A1 (en) 2005-06-16 2009-12-10 Moran Thomas M Methods for Enhancing Immune Responses
US7566456B2 (en) 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
EP1932538A4 (en) * 2005-08-25 2009-10-21 Taiho Pharmaceutical Co Ltd BIODEGRADABLE NANOPARTICLE HAVING RECYCLABLE IMMUNIZED T-EPITOPE PEPTIDE IMMOBILIZED ON OR ENCAPSULATED THEREIN
US20080006554A1 (en) 2006-07-07 2008-01-10 Medtronic Vascular, Inc. Packaging assembly for a catheter
EP2042193A1 (en) * 2007-09-28 2009-04-01 Biomay AG RNA Vaccines
EA023912B1 (ru) * 2008-09-10 2016-07-29 АйТиЭйч ИММЬЮН ТЕРАПИ ХОЛДИНГЗ АБ Лечение воспалительных состояний
RS61098B1 (sr) * 2012-06-15 2020-12-31 Immunomic Therapeutics Inc Nukleinske kiseline za lečenje alergija
EP3541420A2 (en) * 2016-11-16 2019-09-25 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
JP7610349B2 (ja) * 2017-04-22 2025-01-08 イミュノミック セラピューティックス， インコーポレイテッド 改良ｌａｍｐ構築物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001076642A1 (en) * 2000-04-07 2001-10-18 The Regents Of The University Of California Synergistic improvements to polynucleotide vaccines
WO2002080851A2 (en) * 2001-04-05 2002-10-17 The Johns Hopkins University Chimeric vaccines

Also Published As

Publication number Publication date
PL2861240T3 (pl) 2021-07-05
RS61098B1 (sr) 2020-12-31
EP2861240A1 (en) 2015-04-22
AU2019250227B2 (en) 2021-10-21
EP3808361A1 (en) 2021-04-21
US10072053B2 (en) 2018-09-11
KR20200047792A (ko) 2020-05-07
IL270262A (en) 2019-12-31
CA2876824A1 (en) 2013-12-19
IL236174A0 (en) 2015-01-29
AU2018200625A1 (en) 2018-02-15
AU2019250227A1 (en) 2019-11-07
IL236174B (en) 2019-11-28
CN107937423A (zh) 2018-04-20
CN104519896A (zh) 2015-04-15
HRP20201815T1 (hr) 2021-02-19
EP2861240B1 (en) 2020-09-09
IL270260B (en) 2020-08-31
WO2013187906A1 (en) 2013-12-19
CY1123769T1 (el) 2022-05-27
JP5807994B2 (ja) 2015-11-10
PT2861240T (pt) 2020-11-09
BR112014031327B1 (pt) 2022-02-01
CN104519896B (zh) 2017-11-10
US20160271245A1 (en) 2016-09-22
KR102386481B1 (ko) 2022-04-14
IL270261B (en) 2021-03-25
US9744230B2 (en) 2017-08-29
LT2861240T (lt) 2021-01-25
US20180009857A1 (en) 2018-01-11
US20220081474A1 (en) 2022-03-17
AU2012382406A1 (en) 2014-12-18
AU2018200625B2 (en) 2019-09-19
DK2861240T3 (da) 2020-09-28
BR112014031327A2 (pt) 2017-06-27
CA2876824C (en) 2020-07-21
KR102107646B1 (ko) 2020-05-08
AU2012382406A2 (en) 2015-04-16
JP2015521467A (ja) 2015-07-30
SI2861240T1 (sl) 2021-04-30
EP2861240A4 (en) 2016-03-16
HUE052481T2 (hu) 2021-04-28
ES2831723T3 (es) 2021-06-09
KR20150032286A (ko) 2015-03-25

Similar Documents

Publication Publication Date Title
AU2019250227B2 (en) Nucleic acids for treatment of allergies
JP5399895B2 (ja) ワクチン担体
US20190298821A1 (en) Nucleic Acids for Treatment of Peanut Allergies
US20160185831A1 (en) Nucleic acids for treatment of allergies
JP6353510B2 (ja) アレルギー治療のための核酸
HK1253363A1 (zh) 用於治疗变态反应的核酸
JP6088584B2 (ja) アレルギー治療のための核酸
AU2019268022A1 (en) Nucleic acid for treating mite allergy
KR20210007981A (ko) 갑각류 알레르기 치료를 위한 핵산

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 25 MAR 2015

FGA Letters patent sealed or granted (standard patent)